Until recently, conventional prognostication of MDS was performed using the Revised International Prognostic Scoring System (IPSS-R), with adverse prognosis conferred by select mutations (i.e., ASXL1, EZH2, TP53). Here, TP53 is linked to myelodysplastic syndrome.